Related Experiment Video
Updated: Jun 6, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal
Ignacy Tarski1, Jakub Śmiechowicz2, Wiesława Duszyńska2
1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
Background:
Klebsiella pneumoniae MDR/XDR constitutes a difficult to treat bacteria in a number of infections as there are few therapeutic options. Promising drugs in such cases can be cefiderocol, aztreonam and ceftazidime/avibactam or meropenem/vaborbactam.
Case Presentation:
A 72-year-old female patient with sepsis caused by KP NDM, OXA 48 was admitted to the Intensive Care Unit, immediately after an emergency graftectomy (of a recently transplanted kidney) complicated with bleeding. Because of suspicion of intra-abdominal infection, a broad-spectrum empirical antibiotic therapy was initiated (meropenem, vancomycin, colistin). The patient underwent an abdominal revision 48 hours after admission. On the 3rd day of hospitalization, diagnosis of a septic shock with etiology of KP NDM, OXA 48 was made. The strain had sensitivity to a colistin and a cefiderocol. On 13th day in the ICU a relaparotomy was performed. Again, KP strains with sensitivity to cefiderocol only, were cultured from intra-abdominal fluid. Aztreonam, in combination with meropenem/vaborbactam, were included in the treatment and were used together with colistin and tigecycline. In the following days, the inflammatory markers decreased slightly, but the patient's general condition did not improve. On day 27 ceftazidime/avibactam and aztreonam were added, while colistin, meropenem/vaborbactam and fosfomycin were discontinued. On 37th day of hospitalization, cefiderocol became available in hospital and was included in the treatment. Cefiderocol monotherapy was continued for 8 days. After 4 days of cefiderocol treatment, the inflammatory markers CRP and PCT decreased and a significant improvement in patient's condition were observed. On day 56, the patient was transferred to another department.
Conclusion:
A surgical debridement of a source infection, and usage of meropenem/vaborbactam or ceftazidime/avibactam together with aztreonam and colistin allowed survival of the patient but not full recovery. Ultimately, only the cefiderocol monotherapy was effective in treatment of the patient with septic shock of KP NDM OXA 48 etiology.
Insights
Cefiderocol monotherapy effectively treated a patient with septic shock caused by multidrug-resistant Klebsiella pneumoniae (MDR/XDR KP). This offers a promising option for difficult-to-treat infections.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Klebsiella pneumoniae present significant therapeutic challenges.
- Limited effective antibiotic options exist for severe MDR/XDR KP infections.
Observation:
- A 72-year-old female patient with sepsis due to KP NDM, OXA 48 developed septic shock post-kidney transplant surgery.
- Initial broad-spectrum antibiotics were ineffective; serial cultures revealed persistent KP with limited susceptibility.
- The patient's condition showed minimal improvement until cefiderocol monotherapy was initiated.
Findings:
- Cefiderocol monotherapy, initiated on day 37, led to decreased inflammatory markers (CRP, PCT) and significant clinical improvement within 4 days.
- Combination therapies including meropenem/vaborbactam, ceftazidime/avibactam, aztreonam, and colistin provided survival but not full recovery.
Implications:
- Cefiderocol monotherapy demonstrates high efficacy in treating severe infections caused by extensively drug-resistant Klebsiella pneumoniae.
- This case highlights the critical role of novel antibiotics like cefiderocol in managing challenging Gram-negative bacterial infections.
- Early identification of pathogen susceptibility and tailored antibiotic selection are crucial for patient outcomes.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Combined Effects of Drugs: Synergism
Such synergistic combinations...